v-Abl activates c-myc transcription through the E2F site

Area of Science:

• Molecular Biology
• Oncology
• Virology

Background:

• The v-abl oncogene encodes a deregulated nonreceptor tyrosine kinase crucial for Abelson murine leukemia virus transformation.
• v-Abl protein activates c-myc transcription, a key event in the v-Abl-induced cellular transformation process.

Purpose of the Study:

• To elucidate the molecular mechanisms by which v-Abl activates c-myc transcription.
• To identify specific regulatory elements and protein interactions involved in v-Abl-mediated transcriptional control.

Main Methods:

• Development and utilization of a cotransfection assay to study c-myc promoter transactivation by v-Abl.
• Analysis of v-Abl domain requirements (SH1, SH2, C-terminal) for transactivation.
• Identification and characterization of v-Abl-responsive elements within the c-myc promoter.
• Investigation of v-Abl-dependent alterations in protein complexes binding to the c-myc E2F site.

Main Results:

• Transactivation of the c-myc promoter by v-Abl necessitates the SH1 (tyrosine kinase) and SH2 domains; C-terminal domains are dispensable.
• The E2F site within the c-myc promoter was identified as a critical v-Abl-responsive element.
• Multimerized E2F sites conferred v-Abl-dependent activation on a minimal promoter, confirming its role as a response element.
• v-Abl tyrosine kinase activity induced specific changes in E2F-binding proteins, including a complex with DP1, p107, cyclin A, and cdk2.

Conclusions:

• This study provides the first identification of a specific v-Abl response element (E2F site) for transcriptional activation.
• v-Abl-dependent modulation of E2F-binding proteins establishes a significant link between v-Abl oncogene activity, c-myc transcription, cell cycle regulation, and cellular growth control.